100
A Phase III, randomized, double blind study comparing the combination of dabrafenib and trametinib to dabrafenib as first line therapy in subjects with unresectable (Stage IIIc) or metastatic (Stage IV) BRAF V600E/K mutation positive cutaneous melanoma.
What is the MEK 306 (COMBI-d) study?